In-Vitro and In Silico Antiplatelet Action of the New Piperidin4-One-Thiosemicarbazide Derivative

Abstract

Platelets are believed to contribute to hemostasis, thrombosis, inflammation, wound healing, and immunology. R2 is a new thiosemicarbazide derivative of piperidone that is effective in the treatment of angina and ischemia.

In healthy volunteers' blood, compound (R2) reduced platelet aggregation induced by collagen (1-2 µg/ml). R2's effect on PRP was determined using an aggregometer.

R2 reduced platelet aggregation substantially. Without R2, collagen-induced platelet aggregation in PRP was showed 80%, while R2 inhibited 100% platelet aggregation at 1.0625 µM. R2 to have collagen-induced antiplatelet IC50 of 0.5555 ± 0.10 µM. The chosen derivative shows binding energy of -5.73 kcal/mol. Molecular docking analysis revealed significant molecular interactions between Piperidone derivatives and platelet aggregation, suggesting that the drug may be developed further as a platelet aggregation inhibitor. Additionally, the new chemical (R2), a novel thiosemicarbazide derivative, may be beneficial in the treatment of platelet-associated thromboembolic diseases.